A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada

Allergan

Status: Withdrawn

Conditions: Uterine Fibroids

Study type: Observational

Funder types: Industry

Identifiers

NCT04567095

CMO-EPI-WH-0626

Details and patient eligibility

About

This is a non-interventional, cross-sectional survey study to evaluate the effectiveness of the Additional Risk Minimization Measures for Fibristal among Patients in Canada.

Full description

Data will be collected via web-based data capture and paper surveys depending on patient preference. The survey will be conducted in a single wave over 6 months. All data will be maintained in compliance with local regulations.

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have received Fibristal within 6 months of completing the survey.
• Patients who have provided permission to share their responses in aggregate with Health Canada.
• Patients who have provided informed consent for their participation in the survey.

Exclusion criteria

• Patients who participated in the cognitive pre-testing of the survey questionnaire to be used for the study.
• Patients who have been direct employees of Allergan, ICON, Health Canada, or Professional Targeted Marketing (PTM) within the past year.